Steinar Aamdal

  • 5478 Citations
  • 39 h-Index
1984 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Dacarbazine Medicine & Life Sciences
Vaccination Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
apaziquone Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1984 2018

  • 5478 Citations
  • 39 h-Index
  • 104 Article
  • 3 Comment/debate
  • 3 Letter
  • 2 Review article
1 Citations

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

Schöffski, P., Wozniak, A., Kasper, B., Aamdal, S., Leahy, M. G., Rutkowski, P., Bauer, S., Gelderblom, H., Italiano, A., Lindner, L. H., Hennig, I., Strauss, S., Zakotnik, B., Anthoney, A., Albiges, L., Blay, J. Y., Reichardt, P., Sufliarsky, J., van der Graaf, W. T. A., Debiec-Rychter, M. & 6 othersSciot, R., Van Cann, T., Marréaud, S., Raveloarivahy, T., Collette, S. & Stacchiotti, S., Mar 1 2018, In : Annals of Oncology. 29, 3, p. 758-765 8 p., mdx821.

Research output: Contribution to journalArticle

Alveolar Soft Part Sarcoma
Transcription Factors
Organizations
Safety
Research

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’

Schöffski, P., Wozniak, A., Leahy, M. G., Aamdal, S., Rutkowski, P., Bauer, S., Richter, S., Grünwald, V., Debiec-Rychter, M., Sciot, R., Geoerger, B., Marréaud, S., Collette, S., Nzokirantevye, A. & Strauss, S. J., May 1 2018, In : European Journal of Cancer. 94, p. 156-167 12 p.

Research output: Contribution to journalArticle

Alveolar Rhabdomyosarcoma
Protein-Tyrosine Kinases
Confidence Intervals
Disease-Free Survival
anaplastic lymphoma kinase
2 Citations

Acute liver graft rejection after ipilimumab therapy

Dueland, S., Guren, T. K., Boberg, K. M., Reims, H. M., Grzyb, K., Aamdal, S., Julsrud, L. & Line, P. D., Jan 1 2017, In : Annals of Oncology. 28, 10, p. 2619-2620 2 p.

Research output: Contribution to journalLetter

Graft Rejection
Liver
Therapeutics
ipilimumab
5 Citations

Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine

Sioud, M., Nyakas, M., Sæbøe-Larssen, S., Mobergslien, A., Aamdal, S. & Kvalheim, G., Jan 1 2016, In : Case Reports in Medicine. 2016, 9639585.

Research output: Contribution to journalArticle

Indoleamine-Pyrrole 2,3,-Dioxygenase
Dendritic Cells
Immunity
Melanoma
Neoplasm Antigens
7 Citations

Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells

Kyte, J. A., Aamdal, S., Dueland, S., Sæbøe-Larsen, S., Inderberg, E. M., Madsbu, U. E., Skovlund, E., Gaudernack, G. & Kvalheim, G., Nov 1 2016, In : OncoImmunology. 5, 11, e1232237.

Research output: Contribution to journalArticle

Dendritic Cells
Melanoma
Vaccines
Messenger RNA
Neoplasms